Concepts (248)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Analgesics, Opioid | 14 | 2023 | 1371 | 1.910 |
Why?
|
| Glioma, Subependymal | 3 | 2023 | 25 | 1.890 |
Why?
|
| Pineal Gland | 2 | 2022 | 50 | 1.640 |
Why?
|
| Cancer Pain | 8 | 2020 | 312 | 1.620 |
Why?
|
| Palliative Care | 14 | 2023 | 2037 | 1.330 |
Why?
|
| Outpatients | 7 | 2023 | 462 | 1.240 |
Why?
|
| Ventriculostomy | 2 | 2022 | 34 | 1.050 |
Why?
|
| Neoplasms | 22 | 2024 | 15193 | 1.020 |
Why?
|
| Pinealoma | 2 | 2022 | 49 | 1.020 |
Why?
|
| Brain Neoplasms | 7 | 2022 | 4849 | 0.950 |
Why?
|
| Cerebral Ventricle Neoplasms | 1 | 2023 | 81 | 0.890 |
Why?
|
| Glioma | 4 | 2022 | 1963 | 0.890 |
Why?
|
| Meningeal Neoplasms | 3 | 2022 | 441 | 0.870 |
Why?
|
| Hypopituitarism | 1 | 2022 | 33 | 0.860 |
Why?
|
| Craniopharyngioma | 1 | 2022 | 52 | 0.840 |
Why?
|
| Ventriculoperitoneal Shunt | 1 | 2022 | 40 | 0.830 |
Why?
|
| Fibrosarcoma | 1 | 2022 | 135 | 0.800 |
Why?
|
| Levorphanol | 2 | 2023 | 14 | 0.790 |
Why?
|
| Spinal Cord Neoplasms | 1 | 2022 | 142 | 0.760 |
Why?
|
| Pituitary Neoplasms | 1 | 2022 | 203 | 0.740 |
Why?
|
| Hydrocephalus | 1 | 2022 | 217 | 0.710 |
Why?
|
| Benzodiazepines | 2 | 2020 | 170 | 0.680 |
Why?
|
| Social Media | 1 | 2023 | 203 | 0.670 |
Why?
|
| Microcomputers | 1 | 2018 | 36 | 0.650 |
Why?
|
| Physicians' Offices | 1 | 2018 | 15 | 0.650 |
Why?
|
| Methadone | 1 | 2020 | 195 | 0.640 |
Why?
|
| Attitude to Computers | 1 | 2018 | 71 | 0.630 |
Why?
|
| Hypnotics and Sedatives | 1 | 2019 | 218 | 0.620 |
Why?
|
| Professionalism | 1 | 2018 | 52 | 0.610 |
Why?
|
| Empathy | 1 | 2018 | 101 | 0.590 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2022 | 502 | 0.590 |
Why?
|
| Physician-Patient Relations | 3 | 2021 | 792 | 0.580 |
Why?
|
| Medical Records Systems, Computerized | 1 | 2018 | 220 | 0.570 |
Why?
|
| Pain Management | 6 | 2019 | 668 | 0.560 |
Why?
|
| Chronic Pain | 1 | 2020 | 238 | 0.560 |
Why?
|
| Patients | 1 | 2018 | 245 | 0.540 |
Why?
|
| Opioid-Related Disorders | 2 | 2020 | 394 | 0.540 |
Why?
|
| Physicians | 2 | 2021 | 882 | 0.540 |
Why?
|
| Ambulatory Care | 5 | 2021 | 554 | 0.530 |
Why?
|
| Fourth Ventricle | 2 | 2023 | 51 | 0.450 |
Why?
|
| Neurosurgical Procedures | 4 | 2021 | 609 | 0.430 |
Why?
|
| Communication | 1 | 2018 | 876 | 0.400 |
Why?
|
| Sarcoma | 1 | 2022 | 1725 | 0.400 |
Why?
|
| Neurosurgeons | 2 | 2023 | 17 | 0.400 |
Why?
|
| Humans | 58 | 2024 | 261506 | 0.390 |
Why?
|
| Advance Care Planning | 2 | 2023 | 86 | 0.390 |
Why?
|
| Clinical Competence | 2 | 2019 | 1270 | 0.390 |
Why?
|
| Middle Aged | 31 | 2024 | 86204 | 0.380 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2019 | 1303 | 0.370 |
Why?
|
| Fentanyl | 4 | 2022 | 148 | 0.370 |
Why?
|
| Spinal Neoplasms | 3 | 2021 | 631 | 0.370 |
Why?
|
| Retrospective Studies | 19 | 2023 | 37905 | 0.330 |
Why?
|
| Central Nervous System | 2 | 2022 | 436 | 0.320 |
Why?
|
| Intracranial Aneurysm | 2 | 2021 | 123 | 0.320 |
Why?
|
| Male | 32 | 2024 | 123000 | 0.320 |
Why?
|
| Female | 31 | 2024 | 141928 | 0.310 |
Why?
|
| Delirium | 2 | 2020 | 207 | 0.310 |
Why?
|
| Skull Base Neoplasms | 2 | 2021 | 314 | 0.300 |
Why?
|
| Skull Base | 3 | 2021 | 199 | 0.270 |
Why?
|
| Adult | 18 | 2022 | 77950 | 0.270 |
Why?
|
| Substance Abuse, Intravenous | 2 | 2017 | 42 | 0.270 |
Why?
|
| Pain Measurement | 3 | 2021 | 953 | 0.260 |
Why?
|
| Aged | 19 | 2023 | 70117 | 0.250 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2022 | 3890 | 0.230 |
Why?
|
| Pain | 5 | 2023 | 1658 | 0.230 |
Why?
|
| Psychological Tests | 1 | 2024 | 131 | 0.230 |
Why?
|
| Mexican Americans | 2 | 2017 | 322 | 0.230 |
Why?
|
| Substance Abuse Detection | 2 | 2020 | 64 | 0.220 |
Why?
|
| Coccyx | 1 | 2021 | 4 | 0.210 |
Why?
|
| Antiemetics | 1 | 2023 | 125 | 0.200 |
Why?
|
| Vertebral Artery | 1 | 2021 | 42 | 0.200 |
Why?
|
| Perception | 2 | 2021 | 350 | 0.200 |
Why?
|
| Treatment Outcome | 12 | 2022 | 32848 | 0.200 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 1 | 2023 | 134 | 0.200 |
Why?
|
| Oxymorphone | 1 | 2021 | 9 | 0.200 |
Why?
|
| Microwaves | 1 | 2021 | 32 | 0.190 |
Why?
|
| Low Back Pain | 1 | 2021 | 83 | 0.190 |
Why?
|
| Multicenter Studies as Topic | 1 | 2022 | 543 | 0.190 |
Why?
|
| Therapeutic Equivalency | 1 | 2020 | 49 | 0.180 |
Why?
|
| Cryosurgery | 1 | 2021 | 167 | 0.180 |
Why?
|
| Self Report | 1 | 2024 | 756 | 0.180 |
Why?
|
| Haloperidol | 1 | 2020 | 64 | 0.180 |
Why?
|
| Psychomotor Agitation | 1 | 2020 | 78 | 0.180 |
Why?
|
| Infusions, Parenteral | 1 | 2019 | 191 | 0.170 |
Why?
|
| Osteoradionecrosis | 1 | 2020 | 123 | 0.170 |
Why?
|
| Symptom Assessment | 1 | 2021 | 267 | 0.170 |
Why?
|
| Reference Standards | 1 | 2020 | 339 | 0.170 |
Why?
|
| Drug Overdose | 1 | 2019 | 81 | 0.170 |
Why?
|
| Substance-Related Disorders | 1 | 2024 | 524 | 0.170 |
Why?
|
| Hospitals, University | 1 | 2019 | 209 | 0.170 |
Why?
|
| Aged, 80 and over | 8 | 2022 | 29902 | 0.170 |
Why?
|
| Academies and Institutes | 1 | 2018 | 95 | 0.160 |
Why?
|
| Heroin | 1 | 2017 | 24 | 0.160 |
Why?
|
| Psychotropic Drugs | 1 | 2019 | 133 | 0.160 |
Why?
|
| Medical History Taking | 1 | 2018 | 173 | 0.150 |
Why?
|
| Radiography | 1 | 2022 | 1904 | 0.150 |
Why?
|
| Bevacizumab | 1 | 2021 | 938 | 0.150 |
Why?
|
| Single-Blind Method | 1 | 2018 | 409 | 0.150 |
Why?
|
| Family Relations | 1 | 2017 | 88 | 0.150 |
Why?
|
| Walking | 1 | 2019 | 277 | 0.150 |
Why?
|
| Laser Therapy | 1 | 2021 | 411 | 0.150 |
Why?
|
| Cross-Over Studies | 1 | 2018 | 460 | 0.140 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2020 | 4938 | 0.140 |
Why?
|
| Video Recording | 1 | 2018 | 267 | 0.140 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2022 | 2231 | 0.140 |
Why?
|
| Electronic Health Records | 2 | 2021 | 929 | 0.140 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2023 | 7702 | 0.140 |
Why?
|
| Genital Neoplasms, Female | 1 | 2023 | 735 | 0.140 |
Why?
|
| Referral and Consultation | 2 | 2023 | 899 | 0.140 |
Why?
|
| Surveys and Questionnaires | 4 | 2024 | 5687 | 0.140 |
Why?
|
| Dyspnea | 1 | 2019 | 416 | 0.140 |
Why?
|
| Cranial Fossa, Posterior | 1 | 2016 | 49 | 0.140 |
Why?
|
| Tumor Burden | 1 | 2022 | 1987 | 0.140 |
Why?
|
| Antipsychotic Agents | 1 | 2020 | 414 | 0.140 |
Why?
|
| Leadership | 1 | 2018 | 254 | 0.140 |
Why?
|
| United States | 4 | 2023 | 15433 | 0.140 |
Why?
|
| Drug Resistant Epilepsy | 1 | 2018 | 181 | 0.130 |
Why?
|
| Terminal Care | 1 | 2020 | 447 | 0.130 |
Why?
|
| Insurance, Health | 1 | 2017 | 250 | 0.130 |
Why?
|
| Morphine | 3 | 2023 | 308 | 0.130 |
Why?
|
| Wounds, Penetrating | 1 | 2016 | 89 | 0.130 |
Why?
|
| Neurilemmoma | 1 | 2016 | 127 | 0.130 |
Why?
|
| Craniotomy | 1 | 2017 | 304 | 0.130 |
Why?
|
| Time Factors | 4 | 2022 | 12926 | 0.130 |
Why?
|
| Young Adult | 7 | 2022 | 21445 | 0.130 |
Why?
|
| Endovascular Procedures | 1 | 2021 | 516 | 0.130 |
Why?
|
| Documentation | 1 | 2016 | 207 | 0.130 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2023 | 10035 | 0.120 |
Why?
|
| Cancer Care Facilities | 1 | 2019 | 884 | 0.120 |
Why?
|
| Cerebral Cortex | 1 | 2018 | 621 | 0.120 |
Why?
|
| Tumor Microenvironment | 2 | 2022 | 2864 | 0.120 |
Why?
|
| Stress, Psychological | 1 | 2021 | 1000 | 0.120 |
Why?
|
| Social Support | 2 | 2017 | 560 | 0.120 |
Why?
|
| Electroencephalography | 1 | 2018 | 898 | 0.120 |
Why?
|
| Osteosarcoma | 1 | 2021 | 929 | 0.120 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 2016 | 388 | 0.120 |
Why?
|
| Radiation Injuries | 1 | 2021 | 1411 | 0.120 |
Why?
|
| Meningioma | 1 | 2016 | 289 | 0.110 |
Why?
|
| Heroin Dependence | 1 | 2013 | 54 | 0.110 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2014 | 566 | 0.110 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2016 | 551 | 0.110 |
Why?
|
| Education, Medical, Graduate | 1 | 2018 | 671 | 0.110 |
Why?
|
| Endoscopy | 1 | 2016 | 479 | 0.110 |
Why?
|
| Attitude of Health Personnel | 1 | 2018 | 918 | 0.100 |
Why?
|
| Advance Directives | 2 | 2023 | 88 | 0.100 |
Why?
|
| Prognosis | 4 | 2022 | 21713 | 0.100 |
Why?
|
| Hydromorphone | 2 | 2022 | 58 | 0.100 |
Why?
|
| Radiotherapy, Conformal | 1 | 2016 | 902 | 0.100 |
Why?
|
| Precision Medicine | 1 | 2018 | 1154 | 0.090 |
Why?
|
| Prospective Studies | 5 | 2024 | 12873 | 0.090 |
Why?
|
| Hospitalization | 1 | 2019 | 2083 | 0.090 |
Why?
|
| Cross-Sectional Studies | 4 | 2024 | 4314 | 0.090 |
Why?
|
| Survival Rate | 1 | 2022 | 12221 | 0.080 |
Why?
|
| Adolescent | 4 | 2022 | 31252 | 0.080 |
Why?
|
| Risk Factors | 2 | 2022 | 17523 | 0.080 |
Why?
|
| Combined Modality Therapy | 1 | 2019 | 8865 | 0.080 |
Why?
|
| Pancreatic Neoplasms | 1 | 2023 | 5061 | 0.070 |
Why?
|
| Adenocarcinoma | 1 | 2023 | 7789 | 0.060 |
Why?
|
| Double-Blind Method | 2 | 2020 | 2588 | 0.060 |
Why?
|
| Alprazolam | 1 | 2023 | 8 | 0.060 |
Why?
|
| Off-Label Use | 1 | 2023 | 46 | 0.060 |
Why?
|
| Neoplasm Proteins | 1 | 2014 | 3230 | 0.050 |
Why?
|
| Anorexia | 1 | 2023 | 143 | 0.050 |
Why?
|
| Haplorhini | 1 | 2021 | 130 | 0.050 |
Why?
|
| Patient Care Planning | 1 | 2023 | 297 | 0.050 |
Why?
|
| Sus scrofa | 1 | 2021 | 169 | 0.050 |
Why?
|
| Aneurysm, Ruptured | 1 | 2021 | 45 | 0.050 |
Why?
|
| Vomiting | 1 | 2023 | 354 | 0.050 |
Why?
|
| Nausea | 1 | 2023 | 525 | 0.050 |
Why?
|
| Urine | 1 | 2020 | 143 | 0.050 |
Why?
|
| Species Specificity | 1 | 2021 | 777 | 0.050 |
Why?
|
| Clothing | 1 | 2020 | 26 | 0.050 |
Why?
|
| Dogs | 1 | 2021 | 1155 | 0.040 |
Why?
|
| Oral Sprays | 1 | 2019 | 8 | 0.040 |
Why?
|
| Steroids | 1 | 2021 | 356 | 0.040 |
Why?
|
| Administration, Sublingual | 1 | 2019 | 25 | 0.040 |
Why?
|
| Necrosis | 1 | 2021 | 580 | 0.040 |
Why?
|
| Death | 1 | 2020 | 119 | 0.040 |
Why?
|
| Walk Test | 1 | 2019 | 43 | 0.040 |
Why?
|
| Risk Assessment | 2 | 2023 | 6869 | 0.040 |
Why?
|
| Gastrostomy | 1 | 2021 | 180 | 0.040 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2021 | 15862 | 0.040 |
Why?
|
| Adaptation, Psychological | 1 | 2024 | 764 | 0.040 |
Why?
|
| Patient Participation | 1 | 2023 | 446 | 0.040 |
Why?
|
| Trust | 1 | 2020 | 99 | 0.040 |
Why?
|
| Physical Exertion | 1 | 2019 | 113 | 0.040 |
Why?
|
| Quality of Life | 2 | 2023 | 4532 | 0.040 |
Why?
|
| Nurses | 1 | 2019 | 80 | 0.040 |
Why?
|
| Electrodes, Implanted | 1 | 2018 | 183 | 0.040 |
Why?
|
| Demography | 1 | 2019 | 435 | 0.040 |
Why?
|
| Medically Uninsured | 1 | 2017 | 102 | 0.040 |
Why?
|
| Subarachnoid Hemorrhage | 1 | 2017 | 95 | 0.040 |
Why?
|
| Acculturation | 1 | 2017 | 112 | 0.040 |
Why?
|
| Goals | 1 | 2018 | 185 | 0.040 |
Why?
|
| Acne Vulgaris | 1 | 2016 | 47 | 0.040 |
Why?
|
| Infusions, Intravenous | 1 | 2019 | 1382 | 0.040 |
Why?
|
| History, 20th Century | 1 | 2018 | 574 | 0.030 |
Why?
|
| Vulnerable Populations | 1 | 2017 | 167 | 0.030 |
Why?
|
| Interviews as Topic | 1 | 2017 | 497 | 0.030 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2021 | 799 | 0.030 |
Why?
|
| Cisplatin | 1 | 2023 | 2432 | 0.030 |
Why?
|
| Administration, Cutaneous | 1 | 2015 | 141 | 0.030 |
Why?
|
| Blood Loss, Surgical | 1 | 2017 | 309 | 0.030 |
Why?
|
| Cervical Vertebrae | 1 | 2016 | 205 | 0.030 |
Why?
|
| Time-to-Treatment | 1 | 2017 | 292 | 0.030 |
Why?
|
| Insurance Coverage | 1 | 2017 | 256 | 0.030 |
Why?
|
| Qualitative Research | 1 | 2017 | 556 | 0.030 |
Why?
|
| Cytotoxicity Tests, Immunologic | 1 | 2014 | 84 | 0.030 |
Why?
|
| Medicaid | 1 | 2017 | 279 | 0.030 |
Why?
|
| Analgesics | 1 | 2018 | 390 | 0.030 |
Why?
|
| Stents | 1 | 2021 | 1096 | 0.030 |
Why?
|
| Colony-Forming Units Assay | 1 | 2014 | 249 | 0.030 |
Why?
|
| Tyrphostins | 1 | 2014 | 107 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2018 | 1544 | 0.030 |
Why?
|
| Histones | 1 | 2021 | 1466 | 0.030 |
Why?
|
| Pandemics | 1 | 2023 | 1559 | 0.030 |
Why?
|
| Follow-Up Studies | 2 | 2020 | 14889 | 0.030 |
Why?
|
| Mice, Transgenic | 1 | 2021 | 4143 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2019 | 2315 | 0.030 |
Why?
|
| Recurrence | 1 | 2021 | 4758 | 0.030 |
Why?
|
| Decision Making | 1 | 2020 | 1287 | 0.030 |
Why?
|
| Tissue Array Analysis | 1 | 2014 | 760 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2019 | 2803 | 0.030 |
Why?
|
| Healthcare Disparities | 1 | 2017 | 598 | 0.030 |
Why?
|
| Brain Injuries | 1 | 2017 | 787 | 0.020 |
Why?
|
| Interpersonal Relations | 1 | 2013 | 290 | 0.020 |
Why?
|
| Disease Progression | 1 | 2021 | 6682 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2015 | 3472 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2018 | 4971 | 0.020 |
Why?
|
| Surgical Flaps | 1 | 2016 | 927 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2021 | 7222 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2014 | 3033 | 0.020 |
Why?
|
| Pyridines | 1 | 2014 | 1244 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2016 | 4744 | 0.020 |
Why?
|
| Neoplastic Stem Cells | 1 | 2014 | 1443 | 0.020 |
Why?
|
| Cytokines | 1 | 2014 | 2809 | 0.020 |
Why?
|
| Biomarkers, Tumor | 1 | 2021 | 10331 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2018 | 16273 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2014 | 7226 | 0.010 |
Why?
|
| T-Lymphocytes | 1 | 2014 | 3869 | 0.010 |
Why?
|
| Mutation | 1 | 2021 | 15179 | 0.010 |
Why?
|
| Postoperative Complications | 1 | 2016 | 5542 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2014 | 14551 | 0.010 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2014 | 8873 | 0.010 |
Why?
|
| Child | 1 | 2018 | 29154 | 0.010 |
Why?
|
| Animals | 1 | 2021 | 59536 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2014 | 11965 | 0.010 |
Why?
|
| Antineoplastic Agents | 1 | 2014 | 14289 | 0.010 |
Why?
|